Chemoprevention of Colon Cancer by DFMO, Sulindac, and NO-Sulindac Administered Individually or in Combinations in F344 Rats.
NSAIDs
chemoprevention
colorectal cancer
nitric oxide
polyamines
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Aug 2023
07 Aug 2023
Historique:
received:
09
05
2023
revised:
25
07
2023
accepted:
03
08
2023
medline:
12
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
Non-steroidal anti-inflammatory drugs (NSAIDs) are promising colorectal cancer (CRC) chemopreventive drugs; however, to overcome NSAIDs' associated side effects, there is a need to develop safer and efficacious approaches. The present study was designed to evaluate (i) the efficacy of nitric-oxide releasing (NO)-Sulindac as compared to Sulindac; (ii) whether NO-Sulindac is superior to Sulindac in enhancing low-dose difluoromethylornithine (DFMO)-induced chemopreventive efficacy, and (iii) assessing the key biomarkers associated with colon tumor inhibition by these combinations. In F344 rats, colonic tumors were induced by azoxymethane (AOM). At the adenoma stage (13 weeks post AOM), groups of rats were fed the experimental diets containing 0 ppm, 500 ppm DFMO, 150 ppm Sulindac, and 200 ppm NO-Sulindac, individually or in combinations, for 36 weeks. Colon tumors were evaluated histopathologically and assayed for expression levels of proliferative, apoptotic, and inflammatory markers. Results suggest that (except for NO-Sulindac alone), DFMO, Sulindac individually, and DFMO combined with Sulindac or NO-Sulindac significantly suppressed AOM-induced adenocarcinoma incidence and multiplicities. DFMO and Sulindac suppressed adenocarcinoma multiplicity by 63% (
Identifiants
pubmed: 37568816
pii: cancers15154001
doi: 10.3390/cancers15154001
pmc: PMC10417047
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : N01CN35110
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA213987
Pays : United States
Organisme : NCI NIH HHS
ID : RO1-102942
Pays : United States
Organisme : NCI NIH HHS
ID : NO1-CN-35110
Pays : United States
Références
IARC Sci Publ. 1990;(99):159-98
pubmed: 2093648
N Engl J Med. 2002 Apr 4;346(14):1054-9
pubmed: 11932472
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Biochem Pharmacol. 2004 Jun 15;67(12):2197-205
pubmed: 15163551
Carcinogenesis. 2000 Nov;21(11):1935-40
pubmed: 11062151
J Biol Chem. 2000 Dec 8;275(49):38319-28
pubmed: 10978316
Pharmacol Rev. 1991 Jun;43(2):109-42
pubmed: 1852778
J Environ Pathol Toxicol Oncol. 2002;21(2):155-64
pubmed: 12086402
Science. 2002 May 31;296(5573):1644-6
pubmed: 12040179
Cancer Lett. 2011 Jul 28;306(2):205-13
pubmed: 21493000
Nat Rev Cancer. 2004 Oct;4(10):781-92
pubmed: 15510159
Nature. 1980 Sep 11;287(5778):107-8
pubmed: 7432445
Cancer Epidemiol Biomarkers Prev. 1993 Jul-Aug;2(4):369-74
pubmed: 8348060
Cancer Res. 1996 Jun 1;56(11):2556-60
pubmed: 8653697
Cancer Sci. 2004 Jun;95(6):475-80
pubmed: 15182426
Cancers (Basel). 2020 Jul 13;12(7):
pubmed: 32668616
Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1608-12
pubmed: 16030090
Cancer Res. 2001 Apr 15;61(8):3285-9
pubmed: 11309281
Mol Cancer Ther. 2006 Jun;5(6):1530-8
pubmed: 16818512
Nutr Cancer. 2008;60 Suppl 1:30-5
pubmed: 19003578
Cancer Prev Res (Phila). 2009 Nov;2(11):951-6
pubmed: 19892664
PLoS One. 2014 May 06;9(5):e96801
pubmed: 24802416
Science. 2006 Oct 13;314(5797):268-74
pubmed: 16959974
Lancet Oncol. 2002 Mar;3(3):166-74
pubmed: 11902503
Cancer Prev Res (Phila). 2008 Jun;1(1):32-8
pubmed: 18841250
Essays Biochem. 2009 Nov 04;46:111-24
pubmed: 20095973
Cancer Res. 1991 Sep 1;51(17):4528-34
pubmed: 1831401
Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G992-G1004
pubmed: 11292609
Mutat Res. 2004 Nov 2;555(1-2):107-19
pubmed: 15476855
Mol Cancer Ther. 2003 Sep;2(9):885-92
pubmed: 14555707
Fundam Clin Pharmacol. 2003 Feb;17(1):11-20
pubmed: 12588626
Cancer Res. 1995 Apr 1;55(7):1464-72
pubmed: 7882354
Int J Mol Sci. 2018 Aug 08;19(8):
pubmed: 30096840
Cancer Res. 1988 Feb 15;48(4):759-74
pubmed: 3123052
Gastroenterology. 1996 Apr;110(4):1259-62
pubmed: 8613017
J Rheumatol Suppl. 1999 Apr;56:18-24
pubmed: 10225536
Drugs. 2009;69(1):51-69
pubmed: 19192936
Biochem J. 2001 Feb 15;354(Pt 1):217-23
pubmed: 11171097
Gastroenterology. 2004 Mar;126(3):903-13
pubmed: 14988844
Carcinogenesis. 1993 Nov;14(11):2219-25
pubmed: 8242846
J Support Oncol. 2006 Apr;4(4):168
pubmed: 16669458
Cancer Res. 2001 May 1;61(9):3647-52
pubmed: 11325834
Biochem J. 2006 Sep 1;398(2):257-67
pubmed: 16706751
Annu Rev Pharmacol Toxicol. 2002;42:55-80
pubmed: 11807164
Cancer Prev Res (Phila). 2021 Nov;14(11):1009-1020
pubmed: 34341012
Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15069-74
pubmed: 8986765
Biochimie. 2002 Aug;84(8):815-9
pubmed: 12457568
Cancer Res. 2001 Nov 15;61(22):8085-8
pubmed: 11719432
J Biol Chem. 2003 Nov 28;278(48):47762-75
pubmed: 14506281
Gastroenterology. 2010 Sep;139(3):797-805, 805.e1
pubmed: 20538001